0 XP   0   0   0

Sage Therapeutic
Buy, Hold or Sell?

I guess you are interested in Sage Therapeutic. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

Let's analyse Sage Therapeutic

Let's start. I'm going to help you getting a better view of Sage Therapeutic. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

  1. Company's Financial Health
    A deep dive into the books. How are the numbers doing? Is Sage Therapeutic even making a profit? Is the company skyrocketing? Or is it sinking like the Titanic. The trend is your friend.
  2. Market Valuation
    Finally, you now have an insight of how Sage Therapeutic is doing in the market. If the company is worth buying. The latest step is to find out how other investors value Sage Therapeutic. The closing price on 2022-09-30 was $39.16 per share. Is the company over- or underpriced?
  3. Key Performance Indicators
    A total overlook on how the company is doing. Based on the (trends in) the key performance indicators.
Sage Therapeutic Daily Candlestick Chart


Summary

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

1.1. Profitability of Sage Therapeutic.

1.1. Profitability

An important factor of a company's health is the profitability.

1.1.1. Net Profit Margin

Measures how much net profit Sage Therapeutic earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Sage Therapeutic to the Biotechnology industry mean.
  • A Net Profit Margin of -8,190.4% means that $-81.90 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Sage Therapeutic:

  • The MRQ is -8,411.7%. The company is making a huge loss. -2
  • The TTM is -8,190.4%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-8,411.7%TTM-8,190.4%-221.3%
TTM-8,190.4%YOY-4,735.1%-3,455.4%
TTM-8,190.4%5Y-9,799.8%+1,609.3%
5Y-9,799.8%10Y-5,025.5%-4,774.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-8,411.7%-242.4%-8,169.3%
TTM-8,190.4%-275.9%-7,914.5%
YOY-4,735.1%-342.1%-4,393.0%
5Y-9,799.8%-475.7%-9,324.1%
10Y-5,025.5%-561.7%-4,463.8%
1.1.2. Return on Assets

Shows how efficient Sage Therapeutic is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Sage Therapeutic to the Biotechnology industry mean.
  • -7.2% Return on Assets means that Sage Therapeutic generated $-0.07 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Sage Therapeutic:

  • The MRQ is -7.9%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -7.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-7.9%TTM-7.2%-0.7%
TTM-7.2%YOY5.2%-12.4%
TTM-7.2%5Y-8.6%+1.4%
5Y-8.6%10Y-21.4%+12.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-7.9%-9.7%+1.8%
TTM-7.2%-8.7%+1.5%
YOY5.2%-9.2%+14.4%
5Y-8.6%-11.5%+2.9%
10Y-21.4%-12.4%-9.0%
1.1.3. Return on Equity

Shows how efficient Sage Therapeutic is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Sage Therapeutic to the Biotechnology industry mean.
  • -8.4% Return on Equity means the company generated $-0.08 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Sage Therapeutic:

  • The MRQ is -8.4%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -7.6%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-8.4%TTM-7.6%-0.8%
TTM-7.6%YOY5.2%-12.7%
TTM-7.6%5Y-9.7%+2.2%
5Y-9.7%10Y-32.4%+22.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-8.4%-11.8%+3.4%
TTM-7.6%-11.1%+3.5%
YOY5.2%-10.6%+15.8%
5Y-9.7%-13.5%+3.8%
10Y-32.4%-14.5%-17.9%

1.2. Operating Efficiency of Sage Therapeutic.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Sage Therapeutic is operating .

  • Measures how much profit Sage Therapeutic makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Sage Therapeutic to the Biotechnology industry mean.
  • An Operating Margin of -8,271.7% means the company generated $-82.72  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Sage Therapeutic:

  • The MRQ is -8,271.7%. The company is operating very inefficient. -2
  • The TTM is -8,137.0%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-8,271.7%TTM-8,137.0%-134.7%
TTM-8,137.0%YOY-4,764.8%-3,372.1%
TTM-8,137.0%5Y-9,936.8%+1,799.8%
5Y-9,936.8%10Y-5,095.8%-4,841.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-8,271.7%-232.1%-8,039.6%
TTM-8,137.0%-269.6%-7,867.4%
YOY-4,764.8%-309.3%-4,455.5%
5Y-9,936.8%-466.7%-9,470.1%
10Y-5,095.8%-572.5%-4,523.3%
1.2.2. Operating Ratio

Measures how efficient Sage Therapeutic is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 8,654.8% means that the operating costs are $86.55for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Sage Therapeutic:

  • The MRQ is 86.548. The company is inefficient in keeping operating costs low. -1
  • The TTM is 83.686. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ86.548TTM83.686+2.861
TTM83.686YOY48.884+34.802
TTM83.6865Y126.113-42.427
5Y126.11310Y64.673+61.440
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ86.5483.321+83.227
TTM83.6863.542+80.144
YOY48.8843.491+45.393
5Y126.1135.744+120.369
10Y64.6737.007+57.666

1.3. Liquidity of Sage Therapeutic.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Sage Therapeutic is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 1,769.2% means the company has $17.69 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Sage Therapeutic:

  • The MRQ is 17.692. The company is very able to pay all its short-term debts. +2
  • The TTM is 21.142. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ17.692TTM21.142-3.450
TTM21.142YOY26.010-4.868
TTM21.1425Y18.453+2.689
5Y18.45310Y15.359+3.094
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ17.6925.266+12.426
TTM21.1426.060+15.082
YOY26.0106.366+19.644
5Y18.4536.692+11.761
10Y15.3596.457+8.902
1.3.2. Quick Ratio

Measures if Sage Therapeutic is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy (always compare to Biotechnology industry mean)
  • A Quick Ratio of 3,187.6% means the company can pay off $31.88 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Sage Therapeutic:

  • The MRQ is 31.876. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 37.746. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ31.876TTM37.746-5.870
TTM37.746YOY38.577-0.831
TTM37.7465Y30.204+7.542
5Y30.20410Y21.442+8.762
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ31.8764.055+27.821
TTM37.7464.865+32.881
YOY38.5775.192+33.385
5Y30.2045.275+24.929
10Y21.4424.997+16.445

1.4. Solvency of Sage Therapeutic.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Sage Therapeutic assets are financed with debt.

  • Below 1 (100%) is considered healthy (always compare to Biotechnology industry mean).
  • A Debt to Asset Ratio of 0.06 means that Sage Therapeutic assets are financed with 6.1% credit (debt) and the remaining percentage (100% - 6.1%) is financed by its owners/shareholders.

Let's take a look of the Debt to Asset Ratio trends of Sage Therapeutic:

  • The MRQ is 0.061. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.053. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.061TTM0.053+0.008
TTM0.053YOY0.057-0.004
TTM0.0535Y0.079-0.026
5Y0.07910Y0.280-0.201
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0610.271-0.210
TTM0.0530.269-0.216
YOY0.0570.296-0.239
5Y0.0790.361-0.282
10Y0.2800.399-0.119
1.4.2. Debt to Equity Ratio

Measures if Sage Therapeutic is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy (always compare to Biotechnology industry mean).
  • A Debt to Equity ratio of 6.5% means that company has $0.06 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Sage Therapeutic:

  • The MRQ is 0.065. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.056. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.065TTM0.056+0.009
TTM0.056YOY0.062-0.006
TTM0.0565Y0.088-0.032
5Y0.08810Y0.328-0.240
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0650.310-0.245
TTM0.0560.311-0.255
YOY0.0620.310-0.248
5Y0.0880.382-0.294
10Y0.3280.438-0.110

2. Market Valuation of Sage Therapeutic

2. Earnings
2.1. Price to Earnings Ratio

Measures how many years it takes to double your invested money in Sage Therapeutic.

  • Above 15 is considered overpriced but is hard to determine (always use industry average).
  • A PE ratio of -3.79 means the investor is paying $-3.79 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Sage Therapeutic:

  • The EOD is -4.592. Company is losing money. -2
  • The MRQ is -3.787. Company is losing money. -2
  • The TTM is -2.430. Company is losing money. -2
Trends
Current periodCompared to+/- 
EOD-4.592MRQ-3.787-0.804
MRQ-3.787TTM-2.430-1.357
TTM-2.430YOY3.168-5.598
TTM-2.4305Y-8.236+5.806
5Y-8.23610Y-9.019+0.783
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.592-2.115-2.477
MRQ-3.787-2.332-1.455
TTM-2.430-3.889+1.459
YOY3.168-5.087+8.255
5Y-8.236-3.697-4.539
10Y-9.019-3.390-5.629
2.2. Price Earnings to Growth Ratio

Measures the predicted future growth of Sage Therapeutic.

  • Lower is better
  • A PEG ratio of 1 means the investor is paying a fair price for the stock

Let's take a look of the Price Earnings to Growth Ratio trends of Sage Therapeutic:

  • The MRQ is 0.023. Very good. +2
  • The TTM is 0.016. Very good. +2
Trends
Current periodCompared to+/- 
MRQ0.023TTM0.016+0.007
TTM0.016YOY0.039-0.023
TTM0.0165Y0.353-0.337
5Y0.35310Y0.131+0.222
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0230.003+0.020
TTM0.0160.019-0.003
YOY0.0390.042-0.003
5Y0.3530.020+0.333
10Y0.1310.017+0.114

2. Books
2.3. Price to Book Ratio

Measures if the stock price of Sage Therapeutic is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.27 means the investor is paying $1.27 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Sage Therapeutic:

  • The EOD is 1.543. Good. +1
  • The MRQ is 1.273. Good. +1
  • The TTM is 1.337. Good. +1
Trends
Current periodCompared to+/- 
EOD1.543MRQ1.273+0.270
MRQ1.273TTM1.337-0.065
TTM1.337YOY2.744-1.407
TTM1.3375Y4.804-3.466
5Y4.80410Y4.655+0.149
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.5431.843-0.300
MRQ1.2731.961-0.688
TTM1.3372.789-1.452
YOY2.7443.538-0.794
5Y4.8042.782+2.022
10Y4.6552.419+2.236

2.4. Latest News of Sage Therapeutic

Does Sage Therapeutic still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Sage Therapeutic to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2022-09-29
16:51
We're Not Very Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn RateRead

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Sage Therapeutic.

3.1. Institutions holding Sage Therapeutic

Institutions are holding 87.893% of the shares of Sage Therapeutic.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2022-03-31Wellington Management Company LLP11.77170.03976995000-131411-1.844
2022-03-31FMR Inc9.47710.014956315251409512.5671
2022-03-31Vanguard Group Inc7.78330.00364625003467621.0214
2022-06-30Bellevue Group AG5.00351.35752973178-79226-2.5955
2022-03-31State Street Corporation4.77150.0046283535666682630.7501
2022-03-31T. Rowe Price Associates, Inc.3.63250.0072215850474198252.3805
2022-03-31JPMorgan Chase & Co2.71560.00641613650520283.3317
2022-03-31Boxer Capital LLC1.84111.8612109400000
2022-03-31HHG PLC1.73330.01651029953549715.6382
2022-06-30Geode Capital Management, LLC1.60610.004595437323769133.1655
2022-03-31D. E. Shaw & Co LP1.55920.0287926536-67733-6.8123
2022-03-31Palo Alto Investors, LLC1.43332.1795851719699898.9531
2022-03-31First Trust Advisors L.P.1.42140.0286844652332184.0937
2022-03-31Ameriprise Financial Inc1.37260.008815621372994.7922
2022-03-31Artal Group S A1.26221.0394750000-250000-25
2022-03-31Manufacturers Life Insurance Co1.18490.0197704120368896110.0446
2022-03-31Marshall Wace Asset Management Ltd1.0670.03976340335996461743.816
2022-03-31Deutsche Bank AG0.9750.009579342-27800-4.5788
2022-03-31Morgan Stanley - Brokerage Accounts0.9510.002556512227659495.8638
2022-06-30Finepoint Capital LP0.80045.31174756004756000
Total 62.362711.982937057287  

3.2. Funds holding Sage Therapeutic

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2022-03-31BB Biotech AG Ord5.06563.30783010104-160000-5.0472
2022-06-30Fidelity Growth Compy Commingled Pl 34.14360.16532462195813773.418
2022-06-30Fidelity® Growth Company3.22420.15061915912249201.3178
2022-07-31SPDR® S&P Biotech ETF3.02260.82021796115-12558-0.6943
2022-07-31Vanguard Total Stock Mkt Idx Inv2.53170.00421504372279441.8927
2022-07-31Vanguard Small Cap Index2.13720.036126995449140.3884
2022-07-31Hartford MidCap Y1.95620.45941162394-20342-1.7199
2022-07-29iShares Russell 2000 ETF1.8970.072411272329850.0875
2022-06-30Vanguard Health Care Inv1.30050.05577275800
2022-07-31Vanguard Small Cap Growth Index Inv1.25940.0877748352-3457-0.4598
2022-06-30T. Rowe Price New Horizons1.19720.0997711383-3135-0.4388
2022-07-31Vanguard Extended Market Index Investor1.18210.027870243622850.3264
2022-06-30T. Rowe Price Health Sciences1.06950.1323635549-74832-10.5341
2022-06-30Fidelity® Series Growth Company0.96950.1693576113501009.5245
2022-06-30Fidelity® Growth Company K60.87560.1719520305452039.5144
2022-07-29iShares Russell 2000 Value ETF0.87380.145151921700
2022-06-30JPMorgan Small Cap Growth A0.8380.4083497950-3925-0.7821
2022-06-30Fidelity® Select Biotechnology0.8150.322148431116237650.4375
2022-06-30Vanguard Explorer Inv0.80580.084747880300
2022-07-31JPM Global Healthcare C (acc) USD0.76540.318745484500
Total 35.92997.038521350300  

3.3. Insider Transactions

Insiders are holding 12.533% of the shares of Sage Therapeutic.

DateOwnerTypeAmountPricePost Transaction AmountLink
2022-05-05George GolumbeskiBUY800031.458000
2021-08-05Barry E. GreeneBUY2364043.1532440
2021-06-16Barry E GreeneBUY880056.328800
2021-06-16James M FratesBUY181055.11035
2019-12-09Albert RobichaudBUY2500064.16102592
2019-12-09Jeffrey M JonasBUY750064.254530
2019-08-15James M FratesSELL8000160.58
2019-05-28Jeffrey M JonasSELL84661174.8397851
2019-05-24Jeffrey M JonasSELL94264174.75116023
2019-05-22Michael CloonanSELL25000175
2019-05-10Anne Marie CookSELL15000166.1415000
2019-05-06James M FratesSELL8000162.2212235
2019-03-20Steven M PaulSELL60421161.28272777
2019-03-18Steven M PaulSELL3775161.05272777
2019-03-01Kimi IguchiSELL25563156.93
2019-03-01Steven M PaulSELL2600161
2019-02-25Steven M PaulSELL2000161272777
2019-02-19Steven M PaulSELL1543161.62272777
2019-02-15Steven M PaulSELL49461161.02272777
2019-02-08Stephen KanesSELL22948150

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Sage Therapeutic compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Per Share--25.38128.341-10%29.643-14%22.817+11%14.042+81%
Book Value Per Share Growth---2.038-1.889-7%4.672-144%0.921-321%0.668-405%
Current Ratio--17.69221.142-16%26.010-32%18.453-4%15.359+15%
Debt To Asset Ratio--0.0610.053+14%0.057+6%0.079-23%0.280-78%
Debt To Equity Ratio--0.0650.056+15%0.062+4%0.088-26%0.328-80%
Dividend Per Share----0%-0%-0%-0%
Eps---2.130-2.132+0%3.171-167%-1.304-39%-1.020-52%
Eps Growth---167.234-181.893+9%-152.281-9%-41.491-75%27.248-714%
Gains Per Share---2.038-1.889-7%4.672-144%0.921-321%0.668-405%
Gross Profit Margin--1.0001.0000%1.0000%1.037-4%0.998+0%
Net Profit Margin---84.117-81.904-3%-47.351-44%-97.998+17%-50.255-40%
Operating Margin---82.717-81.370-2%-47.648-42%-99.368+20%-50.958-38%
Operating Ratio--86.54883.686+3%48.884+77%126.113-31%64.673+34%
Pb Ratio1.543+18%1.2731.337-5%2.744-54%4.804-74%4.655-73%
Pe Ratio-4.592-21%-3.787-2.430-36%3.168-220%-8.236+117%-9.019+138%
Peg Ratio--0.0230.016+45%0.039-42%0.353-94%0.131-83%
Price Per Share39.160+18%32.30038.063-15%69.823-54%91.906-65%62.566-48%
Quick Ratio--31.87637.746-16%38.577-17%30.204+6%21.442+49%
Return On Assets---0.079-0.072-9%0.052-251%-0.086+9%-0.214+171%
Return On Equity---0.084-0.076-10%0.052-263%-0.097+16%-0.324+285%
 EOD+1 -2MRQTTM+5 -13YOY+4 -145Y+12 -710Y+11 -8

4.2. Fundamental Score

Let's check the fundamental score of Sage Therapeutic based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-4.592
Price to Book Ratio (EOD)Between0-11.543
Net Profit Margin (MRQ)Greater than0-84.117
Operating Margin (MRQ)Greater than0-82.717
Quick Ratio (MRQ)Greater than131.876
Current Ratio (MRQ)Greater than117.692
Debt to Asset Ratio (MRQ)Less than10.061
Debt to Equity Ratio (MRQ)Less than10.065
Return on Equity (MRQ)Greater than0.15-0.084
Return on Assets (MRQ)Greater than0.05-0.079
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Sage Therapeutic based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5047.413
Ma 20Greater thanMa 5040.053
Ma 50Greater thanMa 10039.670
Ma 100Greater thanMa 20036.708
OpenGreater thanClose39.480
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2022-06-30. Currency in USD. All numbers in thousands.

Summary
Total Assets1,601,377
Total Liabilities97,141
Total Stockholder Equity1,504,236
 As reported
Total Liabilities 97,141
Total Stockholder Equity+ 1,504,236
Total Assets = 1,601,377

Assets

Total Assets1,601,377
Total Current Assets1,578,884
Long-term Assets1,578,884
Total Current Assets
Cash And Cash Equivalents 206,510
Short-term Investments 1,307,197
Net Receivables 23,722
Other Current Assets 41,455
Total Current Assets  (as reported)1,578,884
Total Current Assets  (calculated)1,578,884
+/-0
Long-term Assets
Property Plant Equipment 16,317
Other Assets 6,176
Long-term Assets  (as reported)22,493
Long-term Assets  (calculated)22,493
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities89,241
Long-term Liabilities7,900
Total Stockholder Equity1,504,236
Total Current Liabilities
Short-term Debt 7,563
Accounts payable 5,410
Other Current Liabilities 76,268
Total Current Liabilities  (as reported)89,241
Total Current Liabilities  (calculated)89,241
+/-0
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt7,800
Other Liabilities 100
Long-term Liabilities  (as reported)7,900
Long-term Liabilities  (calculated)7,900
+/-0
Total Stockholder Equity
Retained Earnings -1,743,701
Accumulated Other Comprehensive Income -13,872
Capital Surplus 3,262,203
Total Stockholder Equity (as reported)1,504,236
Total Stockholder Equity (calculated)1,504,630
+/- 394
Other
Capital Stock6
Cash and Short Term Investments 1,513,707
Common Stock Shares Outstanding 59,266
Common Stock Total Equity6
Liabilities and Stockholders Equity 1,601,377
Net Debt -191,147
Net Invested Capital 1,504,236
Net Tangible Assets 1,504,236
Net Working Capital 1,489,643
Short Long Term Debt Total 15,363



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-31
> Total Assets 
2,995
0
0
0
8,532
56,777
51,651
137,963
129,665
115,478
228,473
208,410
189,016
303,510
275,630
436,301
404,531
351,168
293,412
251,085
529,937
1,100,652
1,129,483
1,046,999
952,705
1,422,914
1,315,547
1,203,727
1,084,150
944,973
827,242
738,628
2,159,246
2,080,698
2,015,475
1,927,180
1,825,288
1,705,703
1,601,377
1,601,3771,705,7031,825,2881,927,1802,015,4752,080,6982,159,246738,628827,242944,9731,084,1501,203,7271,315,5471,422,914952,7051,046,9991,129,4831,100,652529,937251,085293,412351,168404,531436,301275,630303,510189,016208,410228,473115,478129,665137,96351,65156,7778,5320002,995
   > Total Current Assets 
0
0
0
0
8,407
56,660
51,543
137,790
128,822
114,529
227,508
207,481
188,491
302,606
274,107
434,688
402,579
349,044
291,120
248,343
525,075
1,095,088
1,123,769
1,039,912
944,695
1,371,532
1,263,570
1,152,663
1,035,093
898,236
785,384
698,884
2,122,370
2,051,866
1,988,599
1,901,697
1,800,643
1,682,244
1,578,884
1,578,8841,682,2441,800,6431,901,6971,988,5992,051,8662,122,370698,884785,384898,2361,035,0931,152,6631,263,5701,371,532944,6951,039,9121,123,7691,095,088525,075248,343291,120349,044402,579434,688274,107302,606188,491207,481227,508114,529128,822137,79051,54356,6608,4070000
       Cash And Cash Equivalents 
2,802
0
0
0
8,066
55,425
49,127
136,727
127,766
113,162
224,234
204,877
186,753
299,680
189,003
320,078
168,517
145,460
133,450
134,916
306,235
557,555
325,830
253,123
190,943
342,295
166,185
259,181
126,705
199,444
258,228
184,270
1,661,082
899,250
514,158
422,165
294,233
178,674
206,510
206,510178,674294,233422,165514,158899,2501,661,082184,270258,228199,444126,705259,181166,185342,295190,943253,123325,830557,555306,235134,916133,450145,460168,517320,078189,003299,680186,753204,877224,234113,162127,766136,72749,12755,4258,0660002,802
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
83,292
111,192
228,962
197,104
152,478
108,535
212,613
525,958
766,603
768,278
731,833
1,008,956
1,070,364
863,069
881,688
673,313
498,294
484,267
438,467
1,104,767
1,397,157
1,421,004
1,448,063
1,446,567
1,307,197
1,307,1971,446,5671,448,0631,421,0041,397,1571,104,767438,467484,267498,294673,313881,688863,0691,070,3641,008,956731,833768,278766,603525,958212,613108,535152,478197,104228,962111,19283,29200000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
18,378
0
0
0
0
0
0
0
0
0
0
24,766
48,438
24,185
18,506
19,797
23,722
23,72219,79718,50624,18548,43824,766000000000018,3780000000000000000000000
   > Long-term Assets 
0
0
0
0
125
117
108
173
843
949
965
929
525
904
1,523
1,613
1,952
2,124
2,292
2,742
4,862
5,564
5,714
7,087
8,010
51,382
51,977
51,064
49,057
46,737
41,858
39,744
36,876
28,832
26,876
25,483
24,645
23,459
22,493
22,49323,45924,64525,48326,87628,83236,87639,74441,85846,73749,05751,06451,97751,3828,0107,0875,7145,5644,8622,7422,2922,1241,9521,6131,5239045259299659498431731081171250000
       Property Plant Equipment 
130
0
0
0
86
78
69
134
163
269
285
249
286
865
959
1,049
1,388
1,560
1,443
1,893
4,013
4,295
4,445
5,168
5,643
6,513
8,363
9,365
9,126
8,684
8,077
33,950
31,819
24,171
22,008
20,339
19,125
17,599
16,317
16,31717,59919,12520,33922,00824,17131,81933,9508,0778,6849,1269,3658,3636,5135,6435,1684,4454,2954,0131,8931,4431,5601,3881,049959865286249285269163134697886000130
       Long-term Assets Other 
0
0
0
0
39
39
39
39
39
39
39
39
239
39
564
564
564
564
849
849
849
1,269
1,269
1,919
2,367
6,745
6,390
6,185
6,160
6,061
5,782
5,794
5,057
4,661
4,868
5,144
5,520
5,860
6,176
6,1765,8605,5205,1444,8684,6615,0575,7945,7826,0616,1606,1856,3906,7452,3671,9191,2691,2698498498495645645645643923939393939393939390000
       Deferred Long Term Asset Charges 
0
0
0
0
0
0
0
0
641
641
641
641
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000064164164164100000000
> Total Liabilities 
1,419
0
0
0
40,068
3,124
96,443
5,044
7,780
8,968
11,022
10,306
15,321
16,010
18,421
22,564
36,014
32,722
33,108
51,033
54,462
41,376
51,720
58,494
89,734
103,380
112,672
122,656
139,495
95,767
87,327
81,047
86,912
77,422
85,963
91,526
96,257
87,201
97,141
97,14187,20196,25791,52685,96377,42286,91281,04787,32795,767139,495122,656112,672103,38089,73458,49451,72041,37654,46251,03333,10832,72236,01422,56418,42116,01015,32110,30611,0228,9687,7805,04496,4433,12440,0680001,419
   > Total Current Liabilities 
1,419
0
0
0
2,315
3,088
3,931
5,010
7,757
8,945
11,000
10,291
15,307
15,970
18,339
22,330
35,169
31,882
32,281
49,837
51,951
37,872
47,919
54,526
86,030
68,376
78,953
90,956
112,128
70,360
64,292
59,665
67,204
62,011
71,898
78,942
85,193
77,703
89,241
89,24177,70385,19378,94271,89862,01167,20459,66564,29270,360112,12890,95678,95368,37686,03054,52647,91937,87251,95149,83732,28131,88235,16922,33018,33915,97015,30710,29111,0008,9457,7575,0103,9313,0882,3150001,419
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7,149
0
0
0
0
0
8,620
8,662
7,306
7,358
7,414
7,468
7,523
7,563
7,5637,5237,4687,4147,3587,3068,6628,620000007,1490000000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7,149
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000007,1490000000000000000000000000
       Accounts payable 
1,314
0
0
0
1,988
1,626
3,931
5,010
7,757
8,945
11,000
10,291
15,307
15,970
18,339
22,330
35,169
31,882
32,281
49,837
51,951
37,872
47,919
54,526
86,030
61,207
71,343
83,168
101,884
60,090
55,715
51,045
3,691
3,285
2,917
4,733
10,450
7,129
5,410
5,4107,12910,4504,7332,9173,2853,69151,04555,71560,090101,88483,16871,34361,20786,03054,52647,91937,87251,95149,83732,28131,88235,16922,33018,33915,97015,30710,29111,0008,9457,7575,0103,9311,6261,9880001,314
       Other Current Liabilities 
105
0
0
0
327
1,462
2,069
2,853
5,328
6,163
5,805
7,045
10,148
11,430
12,382
17,093
22,352
23,652
26,239
36,807
42,601
29,522
39,581
48,647
0
7,169
7,610
7,788
10,244
10,270
8,577
55,376
54,851
51,420
61,623
66,795
67,275
63,051
76,268
76,26863,05167,27566,79561,62351,42054,85155,3768,57710,27010,2447,7887,6107,169048,64739,58129,52242,60136,80726,23923,65222,35217,09312,38211,43010,1487,0455,8056,1635,3282,8532,0691,462327000105
   > Long-term Liabilities 
0
0
0
0
37,753
36
92,512
34
23
23
22
15
14
40
82
234
845
840
827
1,196
2,511
3,504
3,801
3,968
3,704
35,004
33,719
31,700
27,367
25,407
23,035
21,382
19,708
15,411
14,065
12,584
11,064
9,498
7,900
7,9009,49811,06412,58414,06515,41119,70821,38223,03525,40727,36731,70033,71935,0043,7043,9683,8013,5042,5111,196827840845234824014152223233492,5123637,7530000
       Deferred Long Term Asset Charges 
0
0
0
0
0
0
0
0
641
641
641
641
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000064164164164100000000
       Warrants
0
0
0
0
0
0
92,472
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000092,472000000
       Other Liabilities 
0
0
0
0
44
36
40
34
23
23
22
15
14
40
82
234
845
840
827
1,196
2,511
3,504
3,801
3,968
3,704
476
410
340
519
456
374
313
270
0
101
103
100
0
100
100010010310102703133744565193404104763,7043,9683,8013,5042,5111,19682784084523482401415222323344036440000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
200
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000200000000000000
> Total Stockholder Equity
1,576
0
0
0
6,173
53,653
-44,792
132,919
121,885
106,510
217,451
198,104
173,695
287,500
257,209
413,737
368,517
318,446
260,304
200,052
475,475
1,059,276
1,077,763
988,505
862,971
1,319,534
1,202,875
1,081,071
944,655
849,206
739,915
657,581
2,072,334
2,003,276
1,929,512
1,835,654
1,729,031
1,618,502
1,504,236
1,504,2361,618,5021,729,0311,835,6541,929,5122,003,2762,072,334657,581739,915849,206944,6551,081,0711,202,8751,319,534862,971988,5051,077,7631,059,276475,475200,052260,304318,446368,517413,737257,209287,500173,695198,104217,451106,510121,885132,919-44,79253,6536,1730001,576
   Common Stock
0
0
0
0
0
0
0
3
3
3
3
3
3
3
3
4
4
4
4
4
5
5
5
5
5
5
5
5
5
5
5
5
6
6
6
6
6
6
6
666666655555555555544444333333330000000
   Retained Earnings Total Equity-1,743,701-1,617,441-1,495,386-1,370,674-1,240,503-1,133,258-1,037,494-2,012,389-1,906,654-1,770,307-1,643,567-1,474,914-1,294,956-1,126,735-963,329-804,941-682,023-665,045-590,447-521,025-447,306-377,105-320,327-264,426-226,630-191,883-161,340-132,778-108,743-83,716-66,845-54,484-44,792000000
   Accumulated Other Comprehensive Income 
0
0
0
0
-95
0
0
0
-146
-146
0
0
-261
0
0
0
-542
0
0
0
-1,073
-1,320
-1,566
-1,853
-1,000
-2,631
2,000
2,000
1,000
-1,000
2,000
1,000
415
-236
-285
-306
-2,660
-11,201
-13,872
-13,872-11,201-2,660-306-285-2364151,0002,000-1,0001,0002,0002,000-2,631-1,000-1,853-1,566-1,320-1,073000-542000-26100-146-146000-950000
   Capital Surplus 
0
0
0
0
0
0
0
187,400
188,727
190,223
326,191
330,879
335,032
479,380
483,797
678,194
688,959
695,645
707,690
721,105
1,066,059
1,724,712
1,760,137
1,793,909
1,827,021
2,446,770
2,496,651
2,554,603
2,587,322
2,620,700
2,645,255
2,669,419
3,109,807
3,137,164
3,170,694
3,207,028
3,227,471
3,247,538
3,262,203
3,262,2033,247,5383,227,4713,207,0283,170,6943,137,1643,109,8072,669,4192,645,2552,620,7002,587,3222,554,6032,496,6512,446,7701,827,0211,793,9091,760,1371,724,7121,066,059721,105707,690695,645688,959678,194483,797479,380335,032330,879326,191190,223188,727187,4000000000
   Treasury Stock000000000-400-400-400-400-400-211-211-211-211-113-17-17-17-170000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
-102
0
0
0
-102
39
39
-35
-119
-98
-84
-32
-142
-396
-356
-468
-726
-506
1,175
1,377
895
-1,192
1,309
2,668,965
3,109,407
3,136,764
3,170,294
3,206,628
3,227,071
3,247,138
3,261,803
3,261,8033,247,1383,227,0713,206,6283,170,2943,136,7643,109,4072,668,9651,309-1,1928951,3771,175-506-726-468-356-396-142-32-84-98-119-353939-102000-10200000000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2021-12-31)

Gross Profit (+$)
totalRevenue6,308
Cost of Revenue-553
Gross Profit5,7555,755
 
Operating Income (+$)
Gross Profit5,755
Operating Expense-466,664
Operating Income-460,909-460,909
 
Operating Expense (+$)
Research Development283,166
Selling General Administrative183,498
Selling And Marketing Expenses-
Operating Expense466,664466,664
 
Net Interest Income (+$)
Interest Income2,883
Interest Expense--2,883
Net Interest Income2,8835,766
 
Pretax Income (+$)
Operating Income-460,909
Net Interest Income2,883
Other Non-Operating Income Expenses134
Income Before Tax (EBT)-457,892-463,926
EBIT - interestExpense = -455,009
-457,892
-460,775
Interest Expense-2,883
Earnings Before Interest and Taxes (ebit)-457,892-460,775
Earnings Before Interest and Taxes (ebitda)-453,710
 
After tax Income (+$)
Income Before Tax-457,892
Tax Provision--
Net Income From Continuing Ops-457,892-457,892
Net Income-457,892
Net Income Applicable To Common Shares-457,892
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses467,217
Total Other Income/Expenses Net3,017-3,017
 

Comments

Join the conversation.

Leave a comment

Stay informed with my latest content.

Subscribe to my newsletter and receive an email as soon as I add content to PenkeTrading.com.


By clicking Register, you agree to the General Terms and Conditions.
Penke's Market Notifications
VOLT.CC
5 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of VOLT.CC.

VOLT.CC Daily Candlestick Chart
VOLLAR.CC
5 hours ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of VOLLAR.CC.

VOLLAR.CC Daily Candlestick Chart
VIB.CC
5 hours ago

I found you a RSI Bullish Hidden Divergence on the daily chart of VIB.CC.

VIB.CC Daily Candlestick Chart
TRIO.CC
5 hours ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of TRIO.CC.

TRIO.CC Daily Candlestick Chart
TKX.CC
5 hours ago

I found you a Golden Cross on the daily chart of TKX.CC.

TKX.CC Daily Candlestick Chart
TERC.CC
5 hours ago

I found you a Three Black Crows Candle Pattern on the daily chart of TERC.CC.

TERC.CC Daily Candlestick Chart
RENTBERRY.CC
5 hours ago

I found you a STOCH Bullish Reversal Divergence on the daily chart of RENTBERRY.CC.

RENTBERRY.CC Daily Candlestick Chart
STOX.CC
5 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of STOX.CC.

STOX.CC Daily Candlestick Chart
STO.CC
5 hours ago

I found you a STOCH Bullish Reversal Divergence on the daily chart of STO.CC.

STO.CC Daily Candlestick Chart
STM.CC
5 hours ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of STM.CC.

STM.CC Daily Candlestick Chart
SPORTS.CC
5 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of SPORTS.CC.

SPORTS.CC Daily Candlestick Chart
SPIRIT.CC
5 hours ago

I found you a STOCH Bullish Reversal Divergence on the daily chart of SPIRIT.CC.

SPIRIT.CC Daily Candlestick Chart
SHIELD.CC
5 hours ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of SHIELD.CC.

SHIELD.CC Daily Candlestick Chart
SHB.CC
5 hours ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of SHB.CC.

SHB.CC Daily Candlestick Chart
SFM.CC
5 hours ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of SFM.CC.

SFM.CC Daily Candlestick Chart
QI.CC
5 hours ago

I found you a Bearish Three Line Strike Candle Pattern on the daily chart of QI.CC.

QI.CC Daily Candlestick Chart
PYRO.CC
5 hours ago

I found you a STOCH Bearish Hidden Divergence on the daily chart of PYRO.CC.

PYRO.CC Daily Candlestick Chart
PTF.CC
5 hours ago

I found you a STOCH Bullish Reversal Divergence on the daily chart of PTF.CC.

PTF.CC Daily Candlestick Chart
PREMIA.CC
5 hours ago

I found you a STOCH Bullish Reversal Divergence on the daily chart of PREMIA.CC.

PREMIA.CC Daily Candlestick Chart
POX.CC
5 hours ago

I found you a Death Cross on the daily chart of POX.CC.

POX.CC Daily Candlestick Chart
PLURA.CC
5 hours ago

I found you a MACD Bearish Reversal Divergence on the daily chart of PLURA.CC.

PLURA.CC Daily Candlestick Chart
PLAY.CC
5 hours ago

I found you a MACD Bullish Hidden Divergence on the daily chart of PLAY.CC.

PLAY.CC Daily Candlestick Chart
PHR.CC
5 hours ago

I found you a Bearish Three Line Strike Candle Pattern on the daily chart of PHR.CC.

PHR.CC Daily Candlestick Chart
PAYT.CC
5 hours ago

I found you a MACD Bearish Hidden Divergence on the daily chart of PAYT.CC.

PAYT.CC Daily Candlestick Chart